- Home
- MGNX vs PSQH Comparison
MGNX vs PSQH Comparison
Compare MGNX & PSQH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- PSQH
- Stock Information
- Founded
- MGNX 2000
- PSQH 2021
- Country
- MGNX United States
- PSQH United States
- Employees
- MGNX N/A
- PSQH N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- PSQH Advertising
- Sector
- MGNX Health Care
- PSQH Consumer Discretionary
- Exchange
- MGNX Nasdaq
- PSQH Nasdaq
- Market Cap
- MGNX 99.7M
- PSQH 105.1M
- IPO Year
- MGNX 2013
- PSQH N/A
- Fundamental
- Price
- MGNX $1.66
- PSQH $2.05
- Analyst Decision
- MGNX Hold
- PSQH Strong Buy
- Analyst Count
- MGNX 6
- PSQH 2
- Target Price
- MGNX $3.20
- PSQH $6.00
- AVG Volume (30 Days)
- MGNX 819.6K
- PSQH 1.4M
- Earning Date
- MGNX 11-04-2025
- PSQH 11-06-2025
- Dividend Yield
- MGNX N/A
- PSQH N/A
- EPS Growth
- MGNX N/A
- PSQH N/A
- EPS
- MGNX N/A
- PSQH N/A
- Revenue
- MGNX $165,495,000.00
- PSQH $27,580,806.00
- Revenue This Year
- MGNX N/A
- PSQH N/A
- Revenue Next Year
- MGNX N/A
- PSQH $38.69
- P/E Ratio
- MGNX N/A
- PSQH N/A
- Revenue Growth
- MGNX 303.47
- PSQH 93.83
- 52 Week Low
- MGNX $0.99
- PSQH $1.55
- 52 Week High
- MGNX $5.10
- PSQH $7.77
- Technical
- Relative Strength Index (RSI)
- MGNX 45.74
- PSQH 48.41
- Support Level
- MGNX $1.82
- PSQH $1.99
- Resistance Level
- MGNX $2.15
- PSQH $2.34
- Average True Range (ATR)
- MGNX 0.14
- PSQH 0.15
- MACD
- MGNX -0.02
- PSQH -0.02
- Stochastic Oscillator
- MGNX 16.95
- PSQH 18.18
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About PSQH PSQ Holdings Inc.
PSQ Holdings Inc operates the website and mobile application named as PublicSq. It is an app and website that connects freedom-loving Americans to high-quality businesses that share values, both online and in local communities. It has three reportable segments comprised of Marketplace; which includes a marketplace platform to access consumers that are drawn to patriotic values and the revenue is generated in the form of advertising and eCommerce transactions, and Brands segment in which through its wholly-owned brand, the company generates revenue from online sales of diapers and wipes and third financial technology which assists consumers, lenders, and retailers in offering point-of-sale financing products.